Altimmune jumps after NY Post highlights this week’s weight loss data

Shares of Altimmune moved higher after Tracy Swartz of the New York Post highlighted recent data for the company’s weight loss drug pemvidutide. Researchers said pemvidutide helped more than 200 overweight adults shed an average of 15.6% of their body weight after 48 weeks, with less muscle lost, Swartz points out, citing data shared this week at the American Diabetes Association’s annual science conference. “These findings demonstrated that the use of pemvidutide may have important effects on the quality of weight loss and cardiometabolic-associated comorbidities of obesity,” said primary investigator Dr. Louis J. Aronne, professor of metabolic research at Weill-Cornell Medical College, the article highlights. Shares of Altimmune are up 7% to $6.72 after the report.